Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling

Area of Science:

• Oncology
• Genitourinary Cancers
• Molecular Targeted Therapy

Background:

• Bladder cancer is a significant global health issue, with standard treatment involving neoadjuvant cisplatin (NAC)-based chemotherapy and cystectomy.
• Advances in understanding bladder cancer genomics reveal key molecular alterations and pathways driving disease progression.
• Targeted therapies and immunotherapies are emerging as crucial treatment modalities for advanced bladder cancer.

Purpose of the Study:

• To review recent preclinical and clinical studies on Fibroblast Growth Factor Receptor (FGFR) inhibitors in bladder cancer.
• To analyze potential mechanisms of drug resistance to FGFR inhibitors.
• To discuss the potential of combining FGFR inhibitors with other therapies, including immunotherapy, to improve patient outcomes.

Main Methods:

• Review of preclinical and clinical studies focusing on FGFR inhibitors in bladder cancer.
• Analysis of molecular alterations and signaling pathways implicated in bladder cancer progression.
• Exploration of combination therapy strategies involving FGFR inhibitors and other agents.

Main Results:

• FGFR inhibitors, such as Erdafitinib, are approved for specific advanced urothelial carcinoma cases with FGFR mutations.
• Preclinical data suggest that combining targeted therapies with immunotherapy may significantly enhance patient outcomes.
• Understanding drug resistance mechanisms is crucial for optimizing FGFR inhibitor efficacy.

Conclusions:

• FGFR inhibitors represent a promising targeted therapy for a subset of bladder cancer patients.
• Combination strategies, particularly with immunotherapy, hold potential for improving treatment efficacy in advanced bladder cancer.
• Further research is needed to overcome resistance and optimize the use of FGFR inhibitors in clinical practice.